FOR IMMEDIATE RELEASE
November 08, 2019
The Osteosarcoma Institute Announces Funding for Clinical Trial and Preclinical Translational Biology Study
Dallas, TX — November 8, 2019 — The Osteosarcoma Institute (OSI) is pleased to announce funding support of
- a clinical trial using a novel approach with two novel agents; and,
- a preclinical translational biology study investigating inhibition of CDK12, a protein involved in cell division that, in preclinical models, has been shown to be critical for osteosarcoma metastasis to the lungs.
The OSI clinical trial grant is to M.D. Anderson Cancer Center in Houston, Texas, for a Phase II multi-arm Study of Durvalumab (anti-PD-L1) and Oleclumab (anti-CD-73) in Adolescents and Young Adults with Recurrent Osteosarcoma. This immunotherapy study will be led by
J. Andrew Livingston, MD, MS and Neeta Somaiah, MD.
Through Case Western Reserve University, in collaboration with Dana-Farber Cancer Institute, OSI is supporting the study of Transcriptional CDK12 inhibition as a Therapeutic Strategy for Metastatic Osteosarcoma. The study is led by Peter Scacheri, PhD, at Case Western and Rani George, MD, PhD, at Dana-Farber.
The OSI review committees chose each of these studies through the lens of the OSI’s mission to improve the life expectancy of relapsed and metastatic osteosarcoma patients. With these scientific investments, OSI aims to provide immediate hope for current patients and long-term hope for better, less toxic treatments for future patients.
Chand Khanna, DVM, PhD, DACVIM (Onc), DACVP (Hon), chair of the OSI Scientific Advisory Board noted, “We are very proud to support these leading edge, game-changing scientific innovations that collectively seek to improve outcomes for patients.”
About the Osteosarcoma Institute
The Osteosarcoma Institute (www.osinst.org, @OSInstitute), is a 501(c)(3) public charity formed in 2017 to dramatically improve treatments for osteosarcoma patients, particularly those with relapsed and metastatic disease. It funds pre-clinical research to gain understanding of the biology of osteosarcoma, and clinical trials to evaluate the safety and effectiveness of potential new treatments.
source: The Osteosarcoma Institute
Click here for a version of this press release.